share_log

Clover Biopharmaceuticals' COVID-19 Booster Candidate Neutralizes Omicron Subvariant During Trial

Clover Biopharmaceuticals' COVID-19 Booster Candidate Neutralizes Omicron Subvariant During Trial

三葉草生物製藥公司的新冠肺炎助推劑候選藥物在試驗期間中和奧密克戎亞型
MT Newswires ·  2022/08/29 22:56

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論